Abstract 646P
Background
AVA6000 is a peptide drug conjugate, in which doxorubicin (dox) is bound by a linker that is specifically cleaved by FAP, which is overexpressed in the TME of many solid tumors.
Methods
The safety, pharmacokinetics (PK) and preliminary efficacy of AVA6000 was studied in a first-in-human, multicenter dose escalation phase I trial. AVA6000 was administered i.v. q3w or q2w using a 3+3 design in patients with locally advanced or metastatic solid tumors categorized as high or middle range FAP (FAPhigh and FAPmid) based on published data. AUC based dosing was used to calculate maximum safe number of cycles of AVA6000 (equivalent to cumulative dox dose of 550mg/m2).
Results
48 pts (median age 60 yr, range 30-79), median 3 prior therapy lines (range, 0-7) received AVA6000 doses of 80 to 385mg/m2 i.v. q3w, and a starting dose of 160mg/m2 given q2w. The safety profile was favorable with both schedules, the most frequent grade 3-4 hematologic toxicities were neutropenia (11%), anemia (6%), and thrombocytopenia (5%). Grade 3 non-hematologic toxicities included mucositis, fatigue and hematemesis (n=1). Two DLTs in the q3w arm were grade 2 cardiac failure (120mg/m2) and grade 4 neutropenia/thrombocytopenia (200mg/m2). Compared to conventional dox, PK showed reduced systemic exposure (AUC, 5-77%) and peak concentration (Cmax, 78-93%), without accumulation suggesting q2w dosing may be optimal. The therapeutic index of free dox was significantly increased, with respect to severe neutropenia, AUC and efficacy. No dose-response relationship was seen between troponin levels and AVA6000 dose. Concentrations of free dox in tumor biopsies (n=11) were ∼2 log scale higher than plasma. PK/PD modeling suggested free dox generation in the TME with an increased plasma distribution half-life. Two PR (RECISTv.1.1) and 3 minor responses (-10 to -29%) were observed in 5 pts with FAPhigh tumor types including salivary gland cancer and soft tissue sarcoma.
Conclusions
AVA6000 delivers high concentration of free dox to the TME relative to plasma, resulting in antitumor activity in FAPhigh tumor types with reduced systemic dox exposure, resulting in lower toxicity versus conventional dox.
Clinical trial identification
NCT04969835.
Editorial acknowledgement
Legal entity responsible for the study
Avacta Group Plc.
Funding
Avacta Group Plc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01